Volume 1.02 | Jan 26

Hematopoiesis News 1.02, January 26, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe


Scientists Discover Cells Critical to Cause and Relapse of Childhood Leukemia
Scientists at The Royal Melbourne Hospital and the University of Melbourne have discovered the cells that cause a common type of childhood leukemia, T cell acute lymphoblastic leukemia. [The University of Melbourne, Melbourne]



A Variant of the Gene Growth Factor Independence 1 (GFI1) Predisposes to a Subtype of Blood Cancer
A large international research group has discovered that a variant of the gene GFI1 predisposes humans to develop acute myeloid leukemia. [Institut de Recherches Cliniques de Montréal, Montréal]

Request A Sample  
Column-Free Isolation of
Hematopoietic Stem and Progenitor Cells
with EasySep®



The Lmo2 Oncogene Initiates Leukemia in Mice by Inducing Thymocyte Self-Renewal
Lmo2 promotes the self-renewal of preleukemic thymocytes, providing a mechanism by which committed T cells can then accumulate additional genetic mutations required for leukemic transformation. [Science]

Transferrin Therapy Ameliorates Disease in Beta-Thalassemic Mice
Results indicate that transferrin is a limiting factor contributing to anemia in these mice and suggest that transferrin therapy might be beneficial in human beta-thalassemia. [Nat Med]

Knockdown of Fanconi Anemia Genes in Human Embryonic Stem Cells Reveals Early Developmental Defects in the Hematopoietic Lineage
Researchers have created a human-specific in vitro system to study early hematopoietic development in Fanconi anemia using a lentiviral RNAi strategy in human embryonic stem cells. [Blood]

Investigation of Murine Spleen as a Niche for Hematopoiesis
Evidence for the maintenance of donor-type myeloid cells after 2 to 4 weeks reflected development from hematopoietic progenitors endogenous to spleen. Overall, this study adds further evidence that spleen can support endogenous myelopoiesis. [Transplantation]

FOG-1-Mediated Recruitment of NuRD is Required for Cell Lineage Re-Enforcement During Hematopoiesis
To test the importance of transcriptional co-factor Friend of GATA1 (FOG-1)/nucleosome remodelling and histone deacetylase (NuRD) interaction for hematopoiesis in vivo, researchers generated mice with a mutation that specifically disrupts FOG-1/NuRD interaction. [EMBO J]

Cyclin C Regulates Human Hematopoietic Stem/Progenitor Cell Quiescence
Researchers have identified an important role of cyclin C (CCNC) in regulating human hematopoietic stem/progenitor cell quiescence, as knocking down CCNC expression in human cord blood CD34+ cells resulted in a significant increase in quiescent cells that maintain CD34 expression. [Stem Cells]

Molecular Signatures of Quiescent, Mobilized and Leukemia-Initiating Hematopoietic Stem Cells
This study compared the gene expression profiles of steady-state bone marrow hematopoietic stem cells (HSCs) to non-self-renewing multipotent progenitors; to HSC treated with mobilizing drugs that expand the HSC pool and induce egress from the marrow; and to leukemic HSC in a mouse model of chronic myelogenous leukemia. [PLoS ONE]

Extrinsic Signals Determine Myeloid-Erythroid Lineage Switch in MN1 Leukemia
To test whether the microenvironment impacts on leukemic phenotype, researchers exploited the MN1 model of acute myeloid leukemia under defined genetically-modified microenvironmental conditions. [Exp Hematol]

The most published medium for hematopoietic CFC assays

by STEMCELL Technologies


United States Researchers To Probe Genetic Changes In Children’s Cancer
Researchers unveiled an unprecedented effort to map the genetic changes of common pediatric cancers to learn more about the underpinnings of the diseases, which could lead to new and better treatments. [The Wall Street Journal]

Oklahoma City Donor Center Will Help State Stem Cell Patients
A $9 million blood donor center being built in Oklahoma City will improve medical care for many state stem cell patients and make way for new technology that can basically "scrub blood" free of bacteria and viruses. [NewsOK Press Release]

Affymax Completes Treatment and Last Patient Follow-up in Phase III Program for Investigational Drug, Hematide(TM), to Treat Anemia in Chronic Renal Failure
Affymax, Inc. announced completion of treatment and follow-up of patients with anemia due to chronic renal failure enrolled in the four-trial, Phase III clinical program for the investigational drug Hematide. [Affymax, Inc. Press Release]


Clarification of SF424 (R&R) Application Instructions for Resubmissions of Revision and Renewal Applications (NOT-OD-10-052) [National Institutes of Health, United States]

Participation of NCCAM on RFA-OD-10-009, Recovery Act Limited Competition: Methodology Development in Comparative Effectiveness Research (RC4) (NOT-AT-10-001) [National Center for Complementary and Alternative Medicine, United States]

Notice of Availability of Administrative Supplements for Activities to Promote Research Collaborations for Projects Currently Funded by the NCI Division of Cancer Biology (NOT-CA-10-015) [National Cancer Institute, United States]

NINDS Ruth L. Kirschstein National Research Service Awards for Individual Predoctoral Fellows in MD-PhD Programs (F31) (PAR-10-091) [National Institutes of Health, United States]


2010 Bone Marrow Transplant Tandem Meetings
February 24-28, 2010
Orlando, United States

36th Annual Meeting of the European Group for Blood & Marrow Transplantation
March 21-24, 2010
Vienna, Austria

12th Biennial CBMTG Conference
April 7-10, 2010
Vancouver, Canada

ISSCR 8th Annual Meeting
June 16-19, 2010
San Francisco, United States

XXXIst International Congress of the ISBT in joint cooperation with the 43rd Congress of the DGTI
June 26-July 1, 2010
Berlin, Germany

ISEH 2010 Meeting
September 15-18, 2010
Melbourne, Australia

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


Business Development Europe – Cell Therapy Products (PALL Corporation)

Research & Development Scientist – Pancreatic Cell Biology (STEMCELL Technologies)

Research & Development Scientist – Endothelial Cell Biology (STEMCELL Technologies)

Research & Development Scientist – Epithelial Cell Biology (STEMCELL Technologies)

Recruit Top Talent

Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.

Visit here to post your career opportunities.

Have we missed an important article or publication in Hematopoiesis News? Click here to submit!


Learn more about Hematopoiesis News: Archives  |  Events  |  Subscribe  |  Contact Us